This week, these five stocks have the best ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.

Curis Inc. (NASDAQ: CRIS) is a drug discovery and development company that engages in the research and development of cancer therapeutics. For more information, get Portfolio Grader’s complete analysis of CRIS stock.

Durect (NASDAQ: DRRX) is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. DRRX gets A’s in Earnings Momentum, Analyst Earnings Revisions, Equity, and Cash Flow as well. The stock has a trailing PE Ratio of 4.8. For more information, get Portfolio Grader’s complete analysis of DRRX stock.

Argan (AMEX: AGX) plans, builds, manages and leases warehouses. AGX also gets A’s in Earnings Growth, Earnings Momentum, and Analyst Earnings Revisions. Shares of the company are up 10.1% from January 1. For more information, get Portfolio Grader’s complete analysis of AGX stock.

Medley Capital (NYSE: MCC) is a private owned investment management firm. Since January 1, the price of MCC has increased 28.7%. This is better than the S%P 500’s 9.8% increase for the same period. For more information, get Portfolio Grader’s complete analysis of MCC stock.

Female Health (NASDAQ: FHCO) markets and manufactures a female condom which can prevent unintended pregnancy and sexually-transmitted diseases. FHCO also gets A’s in Earnings Growth, Earnings Momentum, Analyst Earnings Revisions, and Equity. The price of FHCO is up 64.6% since the first of the year. For more information, get Portfolio Grader’s complete analysis of FHCO stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.